OGEN Quote, Financials, Valuation and Earnings

NanoViricides, Inc. has a net margin of -- compared to Oragenics, Inc.'s net margin of --. Oragenics, Inc.'s return on equity of -509.23% beat NanoViricides, Inc.'s return on equity of -92.29%.

Oragenics, Inc. has a consensus price target of $2.00, signalling upside risk potential of 131.36%. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 530.63%. Given that NanoViricides, Inc. has higher upside potential than Oragenics, Inc., analysts believe NanoViricides, Inc. is more attractive than Oragenics, Inc..

Oragenics, Inc. has a beta of 0.922, which suggesting that the stock is 7.781% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.

Oragenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oragenics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.

Oragenics, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Oragenics, Inc.'s net income of -$3.1M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Oragenics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oragenics, Inc. is 0.53x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Oragenics, Inc.'s net margin of 21.32%. Oragenics, Inc.'s return on equity of -509.23% beat Pfizer Inc.'s return on equity of 10.84%.

Oragenics, Inc. has a consensus price target of $2.00, signalling upside risk potential of 131.36%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Oragenics, Inc. has higher upside potential than Pfizer Inc., analysts believe Oragenics, Inc. is more attractive than Pfizer Inc..

Oragenics, Inc. has a beta of 0.922, which suggesting that the stock is 7.781% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Oragenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. Oragenics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Oragenics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Oragenics, Inc.'s net income of -$3.1M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Oragenics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oragenics, Inc. is 0.53x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Oragenics, Inc.'s net margin of --. Oragenics, Inc.'s return on equity of -509.23% beat Palatin Technologies's return on equity of --.

Oragenics, Inc. has a consensus price target of $2.00, signalling upside risk potential of 131.36%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Oragenics, Inc., analysts believe Palatin Technologies is more attractive than Oragenics, Inc..

Oragenics, Inc. has a beta of 0.922, which suggesting that the stock is 7.781% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Oragenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oragenics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Oragenics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Oragenics, Inc.'s net income of -$3.1M is higher than Palatin Technologies's net income of --. Notably, Oragenics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oragenics, Inc. is 0.53x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to Oragenics, Inc.'s net margin of --. Oragenics, Inc.'s return on equity of -509.23% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Oragenics, Inc. has a consensus price target of $2.00, signalling upside risk potential of 131.36%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3398.25%. Given that Theriva Biologics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Oragenics, Inc..

Oragenics, Inc. has a beta of 0.922, which suggesting that the stock is 7.781% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Oragenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oragenics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Oragenics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Oragenics, Inc.'s net income of -$3.1M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Oragenics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oragenics, Inc. is 0.53x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.